CL2017002652A1 - Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia - Google Patents

Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia

Info

Publication number
CL2017002652A1
CL2017002652A1 CL2017002652A CL2017002652A CL2017002652A1 CL 2017002652 A1 CL2017002652 A1 CL 2017002652A1 CL 2017002652 A CL2017002652 A CL 2017002652A CL 2017002652 A CL2017002652 A CL 2017002652A CL 2017002652 A1 CL2017002652 A1 CL 2017002652A1
Authority
CL
Chile
Prior art keywords
sensitive
delivery system
hypoxia
insulin
vesicles
Prior art date
Application number
CL2017002652A
Other languages
English (en)
Inventor
Zhen Gu
Jicheng Yu
Original Assignee
Univ North Carolina State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State filed Critical Univ North Carolina State
Publication of CL2017002652A1 publication Critical patent/CL2017002652A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0023—Drug applicators using microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
    • A61M2037/0046—Solid microneedles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2207/00—Methods of manufacture, assembly or production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)

Abstract

<p>Se describe un sistema de suministro de insulina de bucle cerrado. De forma más particular, el sistema de suministro de insulina que ahora se desvela pude comprender vesículas sensibles a glucosa que liberan insulina en respuesta a la hipoxia desencadenada por la reducción enzimática de glucosa. Además, o como alternativa a la insulina, el sistema de suministro puede liberar otros agentes de tratamiento de la diabetes, tales como agentes de tratamiento de la diabetes no basados en insulina. Las vesículas pueden prepararse a partir de un polímero sensible a la hipoxia, tal como un ácido hialurónico sensible a la hipoxia (AH-SH). El AH-SH puede comprender grupos hidrofóbicos que pueden reducirse en entornos hipóxicos para formar grupos hidrófilos. Las vesículas pueden cargarse en microagujas y parches de matriz de microagujas para su uso en el tratamiento de la diabetes o para regular de otro modo los niveles de glucosa en sangre en sujetos que necesiten tal tratamiento.</p>
CL2017002652A 2015-04-21 2017-10-19 Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia CL2017002652A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562150622P 2015-04-21 2015-04-21

Publications (1)

Publication Number Publication Date
CL2017002652A1 true CL2017002652A1 (es) 2018-03-23

Family

ID=57144247

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002652A CL2017002652A1 (es) 2015-04-21 2017-10-19 Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia

Country Status (22)

Country Link
US (2) US11191815B2 (es)
EP (2) EP3795143A1 (es)
JP (1) JP6856546B2 (es)
KR (1) KR102624501B1 (es)
CN (2) CN113350489A (es)
AU (2) AU2016252738B2 (es)
BR (1) BR112017022535A2 (es)
CA (1) CA2983289C (es)
CL (1) CL2017002652A1 (es)
CO (1) CO2017011422A2 (es)
DO (1) DOP2017000239A (es)
EC (1) ECSP17073558A (es)
HK (1) HK1245105A1 (es)
IL (1) IL255155A0 (es)
MA (1) MA54623A (es)
MX (1) MX2017013337A (es)
PE (1) PE20180325A1 (es)
PH (1) PH12017501910A1 (es)
RU (1) RU2719584C2 (es)
SG (1) SG11201708509YA (es)
TN (1) TN2017000439A1 (es)
WO (1) WO2016172320A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180325A1 (es) 2015-04-21 2018-02-13 Univ North Carolina State Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
JP7202890B2 (ja) * 2016-02-19 2023-01-12 ノース カロライナ ステート ユニバーシティ 生理学的応答性マイクロニードル送達システムに関連する方法及び組成物
WO2018085809A1 (en) * 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
CN110198730B (zh) * 2016-12-05 2023-10-03 北卡罗莱纳州立大学 H2o2响应性纳米粒子及其用途
DK3548135T3 (da) * 2016-12-05 2021-11-22 Univ North Carolina State Kerne-skal-mikronålsindretninger og anvendelser deraf
WO2018165294A1 (en) 2017-03-07 2018-09-13 North Carolina State University Insulin-responsive glucagon delivery patch
EP3634470A4 (en) * 2017-06-02 2021-03-10 North Carolina State University GLUCOSE-SENSITIVE COMPOSITIONS FOR DRUG DISPENSING
JP6482604B2 (ja) * 2017-06-22 2019-03-13 教裕 南郷 外皮内溶解型ニードル及びニードル装置
US11389405B2 (en) 2017-09-18 2022-07-19 North Carolina State University Artificial beta cells and methods of use thereof
EP3694539A4 (en) 2017-10-10 2021-07-14 North Carolina State University GLUCOSE CARRIER INHIBITOR MODIFIED INSULIN FOR THE DELIVERY OF GLUCOSE SENSITIVE INSULIN
CN111629746B (zh) 2017-11-21 2024-04-16 北卡罗来纳州立大学 具有超快响应的用于葡萄糖触发胰岛素递送的电荷可切换聚合物储库
CN108484848A (zh) * 2018-02-27 2018-09-04 同济大学 一种缺氧响应的聚合物纳米胶束及其制备方法
CN108395489A (zh) * 2018-03-22 2018-08-14 华侨大学 一种2-硝基咪唑-半胱氨酸-海藻酸盐材料及其制备方法
CN108440684A (zh) * 2018-03-22 2018-08-24 华侨大学 一种NI-Cys-Alg自组装纳米载体及其制备方法和应用
EP3765029A4 (en) * 2018-04-13 2021-12-08 North Carolina State University ROS-RESPONSIVE MICRON NEEDLE PLASTER FOR ACNE VULGARIS TREATMENT
CN112153957B (zh) * 2018-04-13 2023-12-26 北卡罗来纳州立大学 微针贴剂促进毛发生长的用途
CN109464657A (zh) * 2018-11-26 2019-03-15 常州工程职业技术学院 一种嵌段共聚物载胰岛素控制释放的方法
CN109568567A (zh) * 2019-01-15 2019-04-05 武汉德丽福生物科技有限公司 一种微针减肥贴片及其制备方法
CN109771659A (zh) * 2019-02-25 2019-05-21 天津大学 一种乏氧响应性纳米药物载体及其制备方法和应用
CN110652494B (zh) * 2019-10-21 2021-09-28 南通大学 一种低氧响应聚氨基酸-peg立构载药胶束及其制备方法
CN110841065A (zh) * 2019-12-05 2020-02-28 福州大学 一种pH/低氧双响应释药协同光动力治疗的纳米复合物及其制备方法
CN115317437B (zh) * 2021-05-11 2023-09-08 中国科学院上海硅酸盐研究所 一种基于胆红素纳米材料的胰岛素递送微针及其制备方法
CN114376569B (zh) * 2022-01-19 2023-10-13 浙江大学 用于救治低血糖的载胰高血糖素可穿戴设备
CN114432243B (zh) * 2022-01-20 2023-08-29 华南师范大学 一种响应pH和葡萄糖的纳米载体及其应用
CN115120552B (zh) * 2022-06-22 2024-06-04 华中科技大学 一种微环境响应释药的多肽载药微针贴片、制备及应用
CN115531309B (zh) * 2022-09-29 2023-08-22 中国药科大学 一种肝靶向聚合物胶束递药系统及其制备方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
US8465468B1 (en) * 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
US20030003048A1 (en) * 2001-04-26 2003-01-02 Chun Li Diagnostic imaging compositions, their methods of synthesis and use
GB0116860D0 (en) 2001-07-10 2001-09-05 Univ Montfort Gel compositions
AU2002337788A1 (en) * 2001-09-28 2003-04-07 Biovalve Technologies, Inc. Microneedle with membrane
WO2003089506A1 (en) 2002-04-22 2003-10-30 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
JP4185423B2 (ja) 2003-09-09 2008-11-26 日本電信電話株式会社 電気化学バイオセンサの製造方法
WO2006088473A2 (en) 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
CN101227940A (zh) * 2005-07-25 2008-07-23 纳米技术维多利亚有限公司 微阵列装置
WO2007075388A2 (en) 2005-12-15 2007-07-05 X-Cell Medical Incorporated Methods of locally treating and preventing cardiac disorders
WO2008011625A2 (en) * 2006-07-21 2008-01-24 Georgia Tech Researh Corporation Microneedle devices and methods of drug delivery or fluid withdrawal
CN101125086A (zh) * 2006-08-18 2008-02-20 刘胜 闭环自动控制胰岛素注射系统
KR101542433B1 (ko) * 2008-02-22 2015-08-06 도레이 카부시키가이샤 마이크로 입자 및 그 의약품 조성물
US7775357B2 (en) 2008-04-14 2010-08-17 Asp Rights Management Pty Limited Syringe disposal device
KR20100037389A (ko) * 2008-10-01 2010-04-09 연세대학교 산학협력단 다중 약물방출조절이 가능한 솔리드 마이크로구조체 및 이의 제조방법
JP5879126B2 (ja) 2008-10-07 2016-03-08 ジン・トゥオＪＩＮ Ｔｕｏ 相転移ポリマーマイクロニードル
CA2750269A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Crystalline insulin-conjugates
EP2419008A1 (en) 2009-04-17 2012-02-22 Sensile Pat AG Medical device for glucose monitoring or regulation
CN102039000B (zh) * 2009-10-20 2015-08-26 苏州纳通生物纳米技术有限公司 一种透皮给药试剂盒
US9557605B2 (en) 2010-10-14 2017-01-31 Merck Patent Gmbh Method of producing liquid crystal display device
GB201101429D0 (en) * 2011-01-27 2011-03-16 Biocompatibles Uk Ltd Drug delivery system
CA2902762A1 (en) * 2012-02-17 2013-08-22 Massachusetts Institute Of Technology Glucose-responsive microgels for closed loop insulin delivery
MX2015015079A (es) 2013-04-30 2016-07-05 Massachusetts Inst Technology Geles de nano-red inyectables para tratamiento de diabetes.
KR102133889B1 (ko) * 2013-06-28 2020-07-14 엘지이노텍 주식회사 회로기판 및 상기 회로기판을 포함하는 조명장치
CN104353062A (zh) * 2014-11-21 2015-02-18 中国人民解放军南京军区福州总医院 一种胰岛素口服纳米制剂及其制备方法
PE20180325A1 (es) 2015-04-21 2018-02-13 Univ North Carolina State Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
US11141486B2 (en) 2015-10-23 2021-10-12 National University Corporation Tokyo Medical And Dental University Drug delivery device
JP7202890B2 (ja) 2016-02-19 2023-01-12 ノース カロライナ ステート ユニバーシティ 生理学的応答性マイクロニードル送達システムに関連する方法及び組成物
WO2018085809A1 (en) 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery

Also Published As

Publication number Publication date
EP3285750B1 (en) 2020-10-21
AU2021204048A1 (en) 2021-07-08
EP3285750A1 (en) 2018-02-28
EP3795143A1 (en) 2021-03-24
CN113350489A (zh) 2021-09-07
WO2016172320A1 (en) 2016-10-27
ECSP17073558A (es) 2018-05-31
NZ736578A (en) 2023-12-22
JP2018513874A (ja) 2018-05-31
US20180110841A1 (en) 2018-04-26
HK1245105A1 (zh) 2018-08-24
KR102624501B1 (ko) 2024-01-11
SG11201708509YA (en) 2017-11-29
US11191815B2 (en) 2021-12-07
MX2017013337A (es) 2018-04-20
JP6856546B2 (ja) 2021-04-07
RU2017139931A (ru) 2019-05-21
RU2017139931A3 (es) 2019-09-16
CO2017011422A2 (es) 2018-03-28
CN107530296B (zh) 2021-06-22
DOP2017000239A (es) 2018-01-15
WO2016172320A8 (en) 2017-11-02
KR20170138542A (ko) 2017-12-15
TN2017000439A1 (en) 2019-04-12
CA2983289C (en) 2023-10-03
EP3285750A4 (en) 2018-12-12
CA2983289A1 (en) 2016-10-27
PE20180325A1 (es) 2018-02-13
US20220160841A1 (en) 2022-05-26
MA54623A (fr) 2021-11-03
CN107530296A (zh) 2018-01-02
BR112017022535A2 (pt) 2018-07-10
AU2016252738B2 (en) 2021-07-08
PH12017501910A1 (en) 2018-03-05
AU2016252738A1 (en) 2017-11-09
RU2719584C2 (ru) 2020-04-21
IL255155A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
CL2017002652A1 (es) Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
BR112016016290A2 (pt) Composições farmacêuticas de insulina de ação rápida, conjunto de infusão, sistema de conjunto de infusão e usos de análogos monoméricos ou diméricos de insulina
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
CL2015002680A1 (es) Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos
BR112014013151A2 (pt) dispositivo de microagulhas incluindo um agente terapêutico peptídeo e um aminoácido, métodos para produzir e usar o dispositivo
AR069704A1 (es) Sistema de administracion de rnai de interferencia y usos del mismo
MX2015012433A (es) Matriz de microestructura para suministro de agentes activos.
CL2011000899A1 (es) Compuestos arilicos, moduladores de la actividad gpr120 en una celula; composicion farmaceutica; y uso de dichos compuestos para el tratamiento de la diabetes tipo i, ii, sindrome metabolico, estimular la produccion de insulina, bajar el nivel de glucosa en la sangre.
BR112018003882A2 (pt) material auxiliar para proporcionar eluição de fármaco de vasos
BR112016002646A2 (pt) dispositivos e métodos de entrega de fármaco de múltiplas unidades
BR112013003160A2 (pt) tratamento de diabetes com células precursoras endócrinas pancráticas
MX2015015079A (es) Geles de nano-red inyectables para tratamiento de diabetes.
PH12015501931B1 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
BR112013027010A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo para sua entrega trasdérmica, e seus usos
BR112021017878A2 (pt) Carbonato de magnésio com superfície reagida, sistema de liberação, formulação de cuidados domiciliares, métodos para preparar um carbonato de magnésio com superfície reagida e para preparar um sistema de liberação, e, uso de um carbonato de magnésio com superfície reagida e de um sistema de liberação
PE20191836A1 (es) Compuesto de insulina acilada
PH12015502556A1 (en) Modified release formulation
SG10201906172XA (en) Regulation of glucose metabolism using anti-cgrp antibodies
BR112013027006A2 (pt) método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo
BR112019001082A2 (pt) gel intestinal de levodopa e carbidopa e métodos de uso
CO2018003759A2 (es) Tratamiento de la neuropatía periférica diabética usando células placentarias
AR081049A1 (es) Medicamento oftalmico para el tratamiento de la hipermetropia
BR112018000525A2 (pt) concentrado contendo alprostadil
TH172399A (th) การบำบัดโรคเบาหวานด้วยสูตรผสมอินซูลินที่ออกฤทธิ์นาน
PL419722A1 (pl) Zastosowanie medyczne kwasu kynureninowego i jego soli do zwolnienia akcji serca oraz zawierająca go kompozycja farmaceutyczna